X4 Pharmaceuticals, Inc. Common Stock XFOR
$3.50
-13.24%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $10.00
- Implied Upside
- +185.3%
- Price Target Range
- $5.00 – $12.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-10 | Wells FargoDerek Archila |
Initiates coverage on | Overweight | $11 |
| 2026-06-02 | Leerink PartnersThomas Smith |
Initiates coverage on | Outperform | $12 |
| 2026-03-09 | GuggenheimMichael Schmidt |
Initiates coverage on | Buy | $12 |
| 2025-12-05 | StifelJames Condulis |
Maintains | Buy | $8 → $10 |
| 2025-11-10 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $4 → $5 |
| 2025-08-29 | StifelStephen Willey |
Maintains | Buy | $30 → $9 |
| 2025-08-13 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $7 → $4 |
| 2025-05-02 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $2 → $7 |
| 2025-03-27 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $45 |
| 2025-03-26 | Cantor FitzgeraldKristen Kluska |
Reiterates | Overweight | $90 |
| 2025-02-07 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $45 |
| 2025-01-14 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $45 |
| 2024-11-14 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $150 → $45 |
| 2024-11-14 | StifelStephen Willey |
Maintains | Buy | $150 → $120 |
| 2024-06-28 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $150 |
| 2024-05-31 | Cantor FitzgeraldKristen Kluska |
Reiterates | Overweight | $150 |
| 2024-04-30 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $90 → $150 |
| 2024-03-22 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $90 |
| 2023-12-12 | B. Riley SecuritiesKalpit Patel |
Downgrades | Buy → Neutral | $90 → $30 |
| 2023-08-11 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $90 |
| 2023-05-17 | StifelStephen Willey |
Maintains | Buy | $120 → $150 |
| 2023-05-05 | HC Wainwright & Co.Swayampakula Ramakanth |
Reiterates | Buy | $90 |
| 2023-04-10 | B. Riley SecuritiesMayank Mamtani |
Maintains | Buy | $210 → $90 |
| 2023-03-24 | OppenheimerLeland Gershell |
Maintains | Outperform | $150 → $120 |
| 2023-03-22 | Cantor FitzgeraldKristen Kluska |
Maintains | Overweight | $90 |
| 2023-03-22 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $150 → $90 |
| 2022-12-22 | Cantor FitzgeraldKristen Kluska |
Initiates coverage on | Overweight | $90 |
| 2022-12-12 | Piper SandlerEdward Tenthoff |
Initiates coverage on | Overweight | $90 |
| 2022-11-30 | HC Wainwright & Co.Swayampakula Ramakanth |
Maintains | Buy | $105 → $150 |
| 2022-05-19 | B. Riley SecuritiesMayank Mamtani |
Maintains | Buy | $300 → $210 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.50
- Market Cap
- $347.51 million
- 52-Week Range
- $1.35 – $4.83
- Average Volume
- 683K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.